Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal first quarter ended July 31, 2012.
Quarterly Results Net sales for the three months ended July 31, 2012 were $52,043,000, a decrease of $4,168,000 or 7% compared to the net sales of $56,211,000, for the three months ended July 31, 2011.
Net sales for generic pharmaceuticals for the three months ended July 31, 2012 were $45,922,000, a decrease of $3,047,000 or 6%, compared to sales of $48,969,000 for the respective prior fiscal period. The decrease was primarily due to lower sales of Fluticasone Propionate nasal spray. Sales of Fluticasone decreased to $22,000,000 from $26,200,000 in the comparable quarter as the Company sold more units at a lower average price. Sales of Dorzolamide ophthalmic products also declined with both unit and pricing decreases. These declines were partially offset by sales of new products such as Lidocaine 5% ointment, launched in March 2012.
ECR Pharmaceuticals contributed $3,095,000 to sales in the current period, a decrease of $612,000 or 17%, compared to sales of $3,707,000 for the respective fiscal 2012 period. The decrease was primarily due to the discontinuation of the Lodrane ® line of antihistamines which the Company stopped shipping August 31, 2012. Sales of discontinued Lodrane ® products totaled approximately $2,400,000 for the three months ended July 31, 2011. Increased sales of Bupap ® and Dexpak ®, in addition to sales from newly acquired brands Tussicaps ® and Orbivan ®, partially offset the decrease in sales for the current period.Net sales for the Health Care Products division, which markets the Company’s OTC branded products, were $3,026,000, a decrease of $509,000 or 14%, compared to $3,535,000 reported for the same period last year. The decrease was primarily due to consumer discounts and promotional pricing on the Nasal Ease ® brand, which were part of the launch plan in major retail chains. These declines were partially offset by sales of our new product Sinus Buster ®, acquired March 2012. Cost of goods sold increased to $26,722,000, or 51% of net sales, for the three months ended July 31, 2012 from $22,975,000, or 41% of net sales, for the three months ended July 31, 2011. The increase in cost of goods sold as a percentage of net sales is primarily due to pricing declines for Fluticasone Propionate nasal spray and Dorzolamide ophthalmic products. Additionally, consumer discounts lowered margins in the HCP division.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV